PTC Therapeutics
PTCT • NASDAQ
PTC Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Matthew Klein, with a market cap of $5.5B.
CEOMatthew Klein
Next Earnings
Upcoming earnings announcement for PTC Therapeutics
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.38
Revenue Estimate
$228.1M
Earnings History
Past 12 earnings reports for PTC Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 19, 2026 | Q4 2025 | -$1.67Est: -$0.33 | -406.1% | $164.7MEst: $295.4M | -44.3% |  10-K |
| Nov 4, 2025 | Q3 2025 | $0.20Est: -$1.14 | +117.5% | $211.0MEst: $175.5M | +20.2% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.83Est: -$1.07 | +22.4% | $178.9MEst: $172.7M | +3.6% | 10-Q |
| May 6, 2025 | Q1 2025 | $10.04Est: -$0.70 | +1534.3% | $1.2BEst: $372.6M | +215.6% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.85Est: -$0.65 | -30.8% | $213.2MEst: $249.0M | -14.4% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$1.39Est: -$1.44 | +3.5% | $196.8MEst: $172.7M | +14.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$1.29Est: -$1.05 | -22.9% | $186.7MEst: $185.9M | +0.4% | 10-Q |
| Apr 25, 2024 | Q1 2024 | -$1.20Est: -$1.24 | +3.2% | $210.1MEst: $169.7M | +23.8% | 10-Q |
| Feb 29, 2024 | Q4 2023 | -$0.24Est: $0.50 | -148.0% | $307.1MEst: $321.3M | -4.4% | 10-K |
| Oct 26, 2023 | Q3 2023 | -$1.76Est: -$1.17 | -50.4% | $196.6MEst: $210.2M | -6.5% | 10-Q |
| Aug 3, 2023 | Q2 2023 | -$1.48Est: -$1.58 | +6.3% | $213.8MEst: $214.0M | -0.1% | — |
| Apr 27, 2023 | Q1 2023 | -$1.88Est: -$1.39 | -35.3% | $220.4MEst: $182.6M | +20.7% | — |